Insulin stimulates glucose transport in its target cells by recruiting the glucose transporter Glut 4 from an intracellular compartment to the cell surface. Previous studies have indicated that phosphatidylinositol 3-kinase (PI 3-kinase) is a necessary step in this insulin action. We have investigated whether PI 3-kinase activation is sufficient to promote Glut 4 translocation in transiently transfected adipocytes. Rat adipose cells were cotransfected with expression vectors that allowed transient expression of epitope-tagged Glut 4 and a constitutively active form of PI 3-kinase (p110*). The expression of p110* induced the appearance of epitopetagged Glut 4 at the cell surface at a level similar to that obtained after insulin treatment, whereas a kinase-dead version of p110* had no effect. The p110* effect was observed over a wide range of the transfected cDNA. When subcellular fractionation of adipocytes was performed, p110* was found, similar to the endogenous PI 3-kinase, enriched in the low density microsomal compartment, which also contains the Glut 4 vesicles. This could suggest that a specific localization of PI 3-kinase in this compartment is required for the action on Glut 4. The observations made with PI 3-kinase are in contrast with those seen with the MAP kinase cascade. Indeed, a constitutively active form of MAP kinase kinase had no effect on Glut 4 translocation in basal conditions. At the highest degree of expression, the constitutively active form of MAP kinase kinase slightly inhibited the insulin stimulation of Glut 4 translocation. Taken together, our results indicate that Glut 4 translocation can be efficiently promoted by an active form of PI 3-kinase but not by the activation of the MAP kinase pathway.
Insulin stimulates glucose transport in its target cells by recruiting the glucose transporter Glut 4 from an intracellular compartment to the cell surface. Previous studies have indicated that phosphatidylinositol 3-kinase (PI 3-kinase) is a necessary step in this insulin action. We have investigated whether PI 3-kinase activation is sufficient to promote Glut 4 translocation in transiently transfected adipocytes. Rat adipose cells were cotransfected with expression vectors that allowed transient expression of epitope-tagged Glut 4 and a constitutively active form of PI 3-kinase (p110*). The expression of p110* induced the appearance of epitopetagged Glut 4 at the cell surface at a level similar to that obtained after insulin treatment, whereas a kinase-dead version of p110* had no effect. The p110* effect was observed over a wide range of the transfected cDNA. When subcellular fractionation of adipocytes was performed, p110* was found, similar to the endogenous PI 3-kinase, enriched in the low density microsomal compartment, which also contains the Glut 4 vesicles. This could suggest that a specific localization of PI 3-kinase in this compartment is required for the action on Glut 4. The observations made with PI 3-kinase are in contrast with those seen with the MAP kinase cascade. Indeed, a constitutively active form of MAP kinase kinase had no effect on Glut 4 translocation in basal conditions. At the highest degree of expression, the constitutively active form of MAP kinase kinase slightly inhibited the insulin stimulation of Glut 4 translocation. Taken together, our results indicate that Glut 4 translocation can be efficiently promoted by an active form of PI 3-kinase but not by the activation of the MAP kinase pathway.
Insulin promotes glucose uptake in muscle and adipose tissue by increasing the translocation of the glucose transporter Glut 4 from an intracellular compartment to the plasma membrane, but the exact molecular mechanism is still undetermined (1, 2) . Following insulin binding, the insulin receptor phosphorylates on tyrosine residues different substrates, including insulin receptor substrate 1 and 2 (IRS1 1 and IRS2) and Src homology collagen (SHC). The phosphorylated IRS1 docks proteins containing Src homology 2 (SH2) domains, such as phosphatidylinositol 3-kinase (PI 3-kinase), Nck, Syp, and Grb2 (3). Thus, the p85 subunit of PI 3-kinase binds through its SH2 domains to the tyrosine phosphorylated YMXM motifs of IRS1 (3); the consequences are an increase in the catalytic activity of the PI 3-kinase p110 subunit (4) and a rise in the intracellular level of PI 3,4-biphosphate and PI 3,4,5-triphosphate. A series of recent data indicates that PI 3-kinase is involved in insulin-induced Glut 4 translocation. For example, the blockade of Glut 4 translocation by pharmacological inhibitors of PI 3-kinase, such as wortmannin or LY294002 (5-8), or by a dominant negative mutant of PI 3-kinase (9, 10) indicates that PI 3-kinase activation is a necessary step for the insulin stimulation of transporter translocation and glucose transport (11) . However, other observations suggest that, although necessary, PI 3-kinase activation is not sufficient to promote glucose transporter translocation. Indeed, growth factors such as platelet-derived growth factor can stimulate PI 3-kinase strongly but have a minor effect on Glut 4 translocation (12, 13) . Further, interleukin 4 (IL-4), which induces tyrosine phosphorylation of IRS1 and activation of PI 3-kinase, does not stimulate Glut 4 translocation in L6 myoblasts (13) . However, it is also possible that PI 3-kinase has to be activated in a specific subcellular compartment (11, 14 -16) , an effect that could occur with insulin but not with platelet-derived growth factor or IL-4. The aim of the present study was to determine whether PI 3-kinase activation was sufficient to promote Glut 4 translocation, using rat adipocytes transiently transfected with a constitutively active form of PI 3-kinase. Adipocytes are transfected with a Glut 4 molecule tagged with a Myc epitope in the first extracellular loop of the protein. By the binding of an anti-Myc antibody to intact cells, Glut 4 translocation is exclusively studied in the small fraction of the cells that have been transfected. This recently described system allows investigation of the signal transduction pathway involved in the translocation of Glut 4 because the epitope-tagged Glut 4 behaves similarly to the endogenous Glut 4 in response to insulin (17, 18) . Taking advantage of this system, we looked directly at the effect of a constitutively active p110 PI 3-kinase (p110*) (19, 20) on Glut 4 translocation, and we determined whether its targeting into the cell was similar to that of the endogenous enzyme. Our results indicate that the active p110* is present in the same intracellular compartment as the endogenous enzyme and is as efficient as insulin in promoting Glut 4 translocation. 
EXPERIMENTAL PROCEDURES

Materials
DNA Vector Constructions
pCIS2 and pCIS-Glut 4myc-pCIS2 is an expression vector containing a cytomegalovirus promoter and enhancer with a generic intron located upstream from the multiple cloning site. This vector gives a high level of protein expression in adipocytes (21) . A unique StuI site was introduced into the nucleotide sequence of the rat Glut 4 cDNA by changing GGTCCT to AGGCCT (coding for Glut 4 Gly 65 -Pro 66 ) using site-directed mutagenesis (CLONTECH). The cDNA was cut with StuI to allow for the insertion of the oligonucleotides coding for the Myc epitope. The sense oligonucleotide was 5Ј-GCA-GAG-GAG-CAA-AAG-CTT-ATT-TCT-GAA-GAG-GAC-TTG-CTT-AAG-3Ј. The antisense oligonucleotide was 5Ј-CTT-AAG-CAA-GTC-CTC-TTC-AGA-AAT-AAG-CTT-TTG-CTC-CTC-TGC-3Ј. This resulted in a fusion gene encoding the peptide sequence (AEEQKLISEEDLLK) inserted between amino acids 65 and 66 in the first exofacial loop of Glut 4. The construction was verified by direct sequencing of the regions surrounding and including the oligonucleotide insert. Glut 4myc was subcloned into the pCIS2 vector.
pCG-p110* and pCG-p110* ⌬kin-pCG p110* encodes for a constitutive form of p110 in which the inter-SH2 domain of p85 was ligated to the NH 2 terminus of p110 (19) . The p110* ⌬kin is a kinase-deficient version of p110* in which the ATP binding site was mutated. Both proteins were tagged at the COOH terminus with the Myc epitope. The engineering of the constructs and description of the vector driving the expression of the proteins have been published previously (19, 20) .
pCEP-MEK*-A constitutively active form of MEK (MEK*) was obtained by deleting the region encompassing amino acids 32-51 and by mutating the two serine residues (218 and 222) to aspartic acid. This form of MEK has been shown to possess high level of kinase activity (22) . This cDNA was subcloned into the mammalian expression vector pCEP (Invitrogen).
pCIS2-v-RAS-The cDNA for human RAS with activating mutation substituting Arg for Val at position 12 (a gift from Dr. de Gunzburg, INSERM, Paris, France) was subcloned in pCIS2.
pADneo-fosluci-pADneo-fosluci is a plasmid containing the c-fos promoter inserted upstream of the luciferase reporter gene and was used to assess the function of the transfected constructs. It was kindly provided to us by Dr. Czernilofsky (Bender Co., Boehringer Ingelheim, Vienna, Austria).
The plasmid DNAs were obtained using a Qiagen maxi kit (QIA-GEN), and their concentration was determined by measuring the A at 260 nm.
Preparation of Isolated Rat Adipocytes and Electroporation
Adipose cells were isolated from epididymal fat pads of male Wistar rats (170 -200 g) by collagenase (Boehringer Mannheim) digestion (23) . Isolated adipocytes were transfected by electroporation as described (17, 18, 21) , with some modifications. Isolated adipocytes were resuspended at a 50% (v/v) cell suspension in Dulbecco's modified Eagle's medium. Cell suspension (400 l) was placed in a 0.4-cm gap cuvette along with the plasmid DNAs (0.25 g pCIS-Glut 4myc and the amounts of the various construct DNAs as indicated in the figure legends). In all cases, the total amount of DNA was adjusted to 10 g by pCIS addition. Electroporation was performed with a double electric shock (800 V, 25 microfarads; 200 V, 1050 microfarads) using an Easyject electroporator (Eurogentec). Cells were diluted in 1.5 ml of Dulbecco's modified Eagle's medium containing 5% BSA (w/v), 25 mM Hepes, pH 7.4, 200 nM (R)-N 6 -1-methyl-2-phenylethyl adenosine and 100 g/ml gentamycin. The cells were incubated for 16 -24 h at 37°C in 5% CO 2 /95% air prior to further study.
Assay for Cell Surface Epitope-tagged Glut 4 Measurement
Electroporated adipocytes were washed twice with Krebs-Ringer bicarbonate buffer containing 30 mM Hepes, pH 7.4 (KRBH) and resuspended at a 10% (v/v) suspension in KRBH, 1% (w/v) BSA. Cells were then incubated for 30 min at 37°C in the absence or presence of insulin (100 nM). After insulin treatment, KCN (final concentration, 2 mM) was added for 5 min to prevent Glut 4 redistribution, and adipocytes were incubated at 25°C for 1 h with 0.5 g/ml mouse monoclonal antibodies to Myc (9E10). Cells were washed three times with KRBH, 1% BSA and incubated in triplicate for 1 h at 25°C with 125 I-labeled sheep anti-mouse IgG (10 Ci/g; final dilution, 1/200) (Amersham Corp.). Then, samples (300 l) were placed on 100 l of dinonylphthalate and centrifuged to separate cells from the medium. The fat cake was boiled in Laemmli buffer (3% SDS, 70 mM Tris, 10% glycerol) and radioactivity associated with the cells was counted in a gamma counter. Radioactivity was normalized by measuring protein concentration in each sample using BCA (Pierce). Nonspecific binding of the antibodies, which represented 30% of the total binding observed in cells transfected with pCIS-Glut 4myc in the absence of insulin stimulation, was obtained with cells transfected with pCIS2 alone and was subtracted from all values.
Subcellular Fractionation of Adipocytes
Adipocytes transfected with pCIS2, pCG-p110*, or pCG-p110* ⌬kin were washed three times with KRBH and homogenized in 2 volumes of 20 mM Tris, pH 7.4, 1 mM EDTA, 250 mM sucrose, and inhibitors of proteases using a Thomas potter type C. Plasma membranes (PMs), low density microsomal membranes (LDMs), and high density microsomal membranes (HDMs) were prepared by differential ultracentrifugation as described (23) . Fraction proteins (50 g) were separated by SDS-PAGE using a 7.5% resolving gel and electrotransferred to a PVDF sheet (Millipore). Immunodetection of epitope-tagged p110* and p110* ⌬kin was performed with rabbit anti-Myc Ig (Santa Cruz), and p85 immunodetection was carried out with polyclonal anti-p85 antibodies (UBI). After washes, sheets were incubated with 125 I-labeled protein A, washed, submitted to autoradiography, and quantified by Molecular Imager analysis (Bio-Rad).
Immunoprecipitation and Immunoblotting of Glut 4myc
Adipose cells were cotransfected with pCIS-Glut 4myc and either pCIS, p110*, or p110* ⌬kin, and cells were washed and homogenized as described above. Total membranes were prepared by centrifugation at 300,000 ϫ g for 1 h and solubilized in 30 mM Hepes, pH 7.4, 30 mM NaCl, 1% Triton X-100, and proteases inhibitors. Then Glut 4Myc was immunoprecipitated using monoclonal anti-Myc antibodies (2 g) coupled to protein G-Sepharose beads. After the washes, the pellets were boiled in Laemmli buffer, and the proteins were separated by SDS-PAGE and transferred on PVDF sheets. Glut 4Myc was immunodetected with a rabbit antipeptide antibody directed against the 12-amino acid peptide corresponding to the COOH-terminal sequence of Glut 4 (24) .
Luciferase Assay
Adipocytes were transfected with pADneo-fosluci (1 g) and 9 g of pCIS, p110*, v-RAS, or pCEP-MEK* as described above. Cells were maintained for 16 -20 h in 5% CO 2 /95% air at 37°C; cells were then resuspended at 10% (v/v) in KRBH, 1% BSA without or with insulin (100 nM) for 6 h. Cells were washed three times in KRBH, and luciferase activity was measured with the Promega kit according to the manufacturer's instructions.
Immunofluorescence Studies
Adipocytes were transfected with pCIS or pCIS-Glut 4myc as described above and incubated for 16 -24 h at 37°C in 5% CO 2 /95% air. Then adipocytes were washed twice with PBS and fixed for 15 min in PBS containing 2% formaldehyde. After permeabilization with PBS, 0.2% Triton X-100 for 15 min, cells were resuspended in PBS, 1% BSA and incubated with antibodies to Myc (final concentration, 10 g/ml) for 1 h. Cells were washed three times with PBS, 1% BSA and incubated for 1 h in the same buffer containing fluorescein-conjugated donkey antimouse IgG (final dilution, 1/200) (Jackson Laboratory). Cells were then washed before visualization under a fluorescence microscope. Fluorescent cells were counted and expressed as a percentage of the total adipocyte number in the same fields.
Statistics
In each experiment, triplicate determination of the binding of the antibodies to Myc was performed. The experiments were repeated 5 or 6 times with different adipocyte preparations. Statistical significance was assessed using Student's t test for paired data.
RESULTS
Efficiency of the Electroporation Process-To estimate the percentage of transfected cells, adipocytes were electroporated with pCIS or pCIS-Glut 4myc. Twenty-four hours later, cells were fixed and permeabilized before successive incubations with an antibody to the Myc epitope and a fluorescein-conjugated secondary antibody. As shown in Fig. 1B , immunofluorescence was visible in adipocytes transfected with pCIS-Glut 4myc but not in mock-transfected adipocytes (Fig. 1C) . Comparison between the number of cells exhibiting fluorescence and the total number of adipocytes in the same fields indicated that the transfection protocol efficiency was about 10%. The total level of Glut 4 in cells transfected with pCIS or pCIS-Glut 4myc was quantified by immunoblotting with an antibody to Glut 4. As shown in Fig. 1D , transfection of adipocytes with pCIS-Glut 4myc induced a 1.1-1.2-fold increase in Glut 4 expression. Taking into account the percentage of transfected cells, this result indicates that the level of Glut 4 was increased 2-3-fold in transfected adipocytes.
Subcellular Distribution of p110* and p110*⌬kin-We first looked at the expression of the different PI 3-kinase constructs and at their subcellular distribution in comparison with the endogenous protein. Adipocytes were transfected with an empty vector, with the active form of PI 3-kinase (p110*), or with its kinase-dead version (p110*⌬kin). They were fractionated in PMs, LDMs, HDMs, and cytosols. Fraction proteins (50 g) were separated by SDS-PAGE and immunoblotted with anti-Myc antibody to detect p110* and p110*⌬kin or with an antibody against the p85 subunit to detect the endogenous PI 3-kinase. Typical autoradiograms are shown in Fig. 2 (top  panels) , and the quantification of four subcellular fractionations is presented in Fig. 2 (lower panel) . When expressed per mg of proteins, the largest concentrations of the endogenous p85 PI 3-kinase were found in plasma membranes and LDMs. When the total amounts of proteins in each fraction were taken into account (Table I) , the majority of p85 (66%) was found in the cytosol, and the remainder was equally distributed between the PM and the LDM. These results, which are in agreement with the previously reported subcellular distribution of p85 in adipocytes (15) , indicate that the electroporation procedure did not affect the repartition of endogenous PI 3-kinase. The subcellular distribution of p110* (Fig. 2 and Table I ) and p110* ⌬kin (data not shown) paralleled that of the endogenous p85 protein with a higher LDM concentration.
Effect of p110* and p110*⌬kin on Epitope-tagged Glut 4 Translocation-To investigate whether PI 3-kinase activation was sufficient to promote Glut 4 translocation, we compared rat adipocytes cotransfected with pCG-p110* and pCIS-Glut 4myc with cells cotransfected with pCIS2 (an empty expression vector) and pCIS-Glut 4myc (control cells) (Fig. 3A) . In control cells, insulin induced a 3.2-fold recruitment of Glut 4Myc to the cell surface, an effect similar to that previously described (17, 18) . When p110* (9 g) was cotransfected with Glut 4myc, the level of Glut 4Myc at the cell surface was enhanced 4-fold compared to basal levels in control cells and was similar to the amount reached following insulin stimulation in control cells. A stimulatory effect was also observed with much lower amounts (0.5-1 g) of p110*. As shown in the inset (Fig. 3A) , the expression of p110* appeared proportional to the amount of the transfected DNA. This result suggests that the expression of a constitutively active PI 3-kinase was sufficient to trigger glucose transporter translocation. Insulin treatment of p110*-transfected adipocytes resulted in a further slight increase in the amount of Glut 4Myc present at the cell surface. These effects of p110* were dependent on its kinase activity because expression of kinase-dead p110* (p110*⌬kin) did not modify Glut 4Myc translocation compared to control cells. Because it has been shown in Chinese hamster ovary cells that the p110* construct was able to activate the RAS pathway (19), we tested the ability of p110* to stimulate the activity of the c-fos promoter in adipocytes (Table II) . We cotransfected p110* and v-RAS with pADneo-fosluci, a plasmid with the c-fos promoter driving a luciferase reporter gene, and measured the effect of those constructs on luciferase activity. As shown in Table II, whereas v-RAS increased the luciferase activity as expected, p110* had no effect.
To verify that the transfection of p110* and p110*⌬kin did not alter the expression level of the epitope-tagged transporter, Glut 4Myc was immunodetected in total membrane with an anti-Glut 4 antibody following immunoprecipitation with antiMyc antibodies. As shown in Fig. 3B , Glut 4Myc was expressed at a similar level in all groups of cells. This indicates that the effect of p110* was probably caused by recruitment of Glut 4Myc from an intracellular pool and was not related to alterations in the total amount of Glut 4Myc expressed in the various groups of cotransfected cells.
Effect of MEK* on Epitope-tagged Glut 4 Translocation-To investigate whether the MAP kinase pathway could also modify Glut 4 translocation, we transfected adipocytes with MEK*. As shown in Table II , cells cotransfected with pCEP-MEK* showed a marked increase in luciferase activity, indicating that MEK* was constitutively active. However, as shown in Fig. 4,   FIG. 2 . Subcellular localization of the endogenous PI 3-kinase and of p110* in adipocytes. Adipocytes were transiently transfected as described under "Experimental Procedures" with 9 g of p110*. Subcellular fractionation of the adipocytes was performed 24 h later to yield PMs, LDMs, HDMs, and cytosol (CYTO). Proteins (50 g) were separated by SDS-PAGE, electrotransferred to PVDF, and subjected to immunoblotting for the presence of p110* with antibody to Myc or to p85. A typical autoradiogram is shown in the top panels. The lower panel represents the quantification performed by Molecular Imager (mean Ϯ S.E. of four independent experiments), in which results were normalized to the concentration of p110* or p85 present in the plasma membranes.
TABLE I Subcellular localization of the endogenous PI 3-kinase and of
p110* in adipocytes Adipocytes were transiently transfected as described under "Experimental Procedures" with 9 g of constitutively active p110*. Subcellular fractionation of the adipocytes was performed 24 h later to give PMs, LDMs, HDMs, and cytosol. Proteins (50 g) were separated by SDS-PAGE, electrotransferred to PVDF, and subjected to immunoblotting for the presence of p110* using an antibody to myc or to p85 (endogenous PI 3-kinase). The quantification of the autoradiograms was performed by Molecular Imager. Results were calculated taking into account the total protein amounts recovered in each fraction and were expressed as a percentage of the total cellular enzyme (mean Ϯ S.E. of 5 or 6 independent experiments). Values are presented as the mean Ϯ S.E. of three to six experiments performed with different cell preparations. The effect of insulin is significant compared to basal conditions in pCIS2 cells (p Ͻ 0.001), 9 g p110* cells (p Ͻ 0.025), and p110*⌬kin cells (p Ͻ 0.001) using Student's t test for paired analysis. In the inset of panel A, the expression of p110* is shown at various plasmid concentrations; adipocyte homogenate proteins were separated by SDS-PAGE and immunoblotted with an antibody to Myc. B, 24 h after transfection, adipocytes were homogenized and total membrane fractions were prepared and solubilized with 1% Triton X-100. Proteins (100 g) were immunoprecipitated with 2 g of anti-Myc antibodies, separated by SDS-PAGE and immunoblotted with antibodies to Glut 4 as described under "Experimental Procedures." Triplicate determinations were performed under each condition.
the basal level of cell surface Glut 4Myc was similar in control cells and cells transfected with two different amounts of MEK*, suggesting that MEK activation, in contrast to PI 3-kinase activation, did not promote Glut 4 translocation. At the highest MEK* concentration, insulin stimulation of Glut 4Myc translocation was reduced by 50% compared to control cells, but no effect was observed at low concentration. Whatever the MEK* amount used, the expression of Glut 4Myc was not affected compared to pCIS2 conditions (data not shown).
DISCUSSION
Several studies have focused on the role of PI 3-kinase in the stimulation of glucose transport by insulin. The use of pharmacological inhibitors of the enzyme or of a dominant negative mutant clearly indicates that PI 3-kinase activation is required for the insulin stimulation of Glut 4 translocation (5-10). However, in these studies, the question of whether PI 3-kinase was sufficient to promote glucose transporter translocation was not addressed. To directly investigate whether PI 3-kinase can promote glucose transporter translocation, we have taken advantage of a form of PI 3-kinase (p110*) that was constitutively active in a growth factor-independent manner (19, 20) . We used transfected adipocytes that transiently express epitope-tagged Glut 4 and the other proteins of interest. This system allows for a direct measurement of the level of cell surface Glut 4Myc by the binding of anti-Myc antibodies on intact cells (17, 18, 21) . Previous studies have demonstrated that Glut 4Myc behavior is similar to that of endogenous Glut 4, and thus the cell surface Glut 4Myc level reflects the translocation of endogenous Glut 4. The use of an epitope-tagged Glut 4 is thus a reporter for Glut 4 subcellular distribution exclusively in the fraction of cells that are transfected, which was about 10% in our transfection conditions. The level of Glut 4 overexpression was thus estimated to be increased only 2-3-fold in the Glut 4Myc-expressing cells. With this moderate level of overexpression, it is unlikely that the normal sorting mechanisms were saturated. Indeed, in adipocytes of transgenic mice that markedly overexpressed Glut 4 (15-20 fold) in fat tissue, the transporters appeared to be targeted to the same unique structurally defined vesicles as in native cells (25) .
Using transiently transfected adipocytes, we found that p110* promoted Glut 4Myc translocation very efficiently. Indeed, the level of Glut 4Myc at the cell surface was comparable to the level of Glut 4Myc present at the cell surface of control adipocytes stimulated with insulin. The level of p110* overexpression could not be appreciated by comparison with the endogenous protein because no antibody was able to recognize the rat p110 PI3 kinase subunit. However, it could be observed that the p110* effect on Glut 4Myc subcellular distribution was observed at various levels of p110* expression. The increase in Glut 4Myc at the cell surface was dependent on the p110* kinase activity because it was not observed when a kinase-dead form of p110* was expressed. This effect was not due to a change in Glut 4Myc expression. We can also exclude the possibility that it is related to a RAS pathway activation because the p110* overexpression was not able to activate the c-fos promoter. This result differs from the observations in Chinese hamster ovary cells, where this construct activated the RAS pathway (19) . It should be noted that the relationship between PI 3-kinase and RAS is a matter of debate. Some observations indicate that PI 3-kinase could be upstream, downstream, or independent of RAS; these observations are perhaps related to cell-type differences (for a review, see Ref. 26) . In contrast to the p110* effect, transfection of a constitutively active MEK did not modify basal Glut 4Myc level at the cell surface. These data reinforce the idea that stimulation of the MAP kinase cascade is not involved in Glut 4 translocation (27) (28) (29) . Using the same approach, v-RAS was able to promote an increase in Glut 4Myc at the cell surface (10) . The difference with our results suggests that the RAS effect was not due to activation of MEK or MAP kinase but was more likely due to the stimulation of another branching signaling pathway. The high expression of MEK* reduced insulin effect on Glut 4Myc translocation, an effect that was not observed with a lower expression. These observations suggest that the inhibitory effect of MEK* is likely to be due to the saturation of downstream molecules and not to its high kinase activity. However, it remains possible that the MAP kinase pathway is involved in a negative feedback loop.
Our present demonstration that a constitutively active PI 3-kinase is sufficient to increase Glut 4 level at the plasma membrane, together with the observation that inhibition of PI 3-kinase blocks insulin stimulation of glucose transport translocation, suggests that the insulin effect on glucose transporter translocation is mainly due to activation of PI 3-kinase. Our results are in agreement with the observation that overexpression of IRS1 in adipocytes is able to trigger glucose transporter translocation in the absence of insulin stimulation (17) . In this case the high level of IRS1 expression could compensate the low level of tyrosine kinase activity of the insulin receptor, leading to a sufficient tyrosine phosphorylation of IRS1 and thus to activation of PI 3-kinase. However, our results are at variance with two recent studies using different approaches, which led to the conclusion that activation of PI 3-kinase was not sufficient and that an alternative signaling pathway was required for stimulation of glucose uptake. In one study (30) , although PI 3-kinase was activated in 3T3-L1 adipocytes by thiophosphorylated peptides corresponding to the binding motif of PI 3-kinase to IRS1, only a minor effect on Glut 4 translocation was observed. In the other study (13) , IL-4 stimulation of L6 myoblasts expressing the IL-4 receptor induced IRS1 tyrosine phosphorylation and increased PI 3-kinase activity but had no effect on glucose uptake. It should be noted that only the cytosolic (30) or total (13) PI 3-kinase activity was measured. However, activation of PI 3-kinase and extensive tyrosine phosphorylation of IRS1 occur in the LDM fraction (14 -16, 31) , and PI 3-kinase activation has been observed in Glut 4-containing vesicles (32) . Interestingly, platelet-derived growth factor increased total PI 3-kinase activity but did not stimulate PI 3-kinase activity in the LDM and did not stimulate Glut 4 translocation in comparison with insulin (16). Therefore, it is possible that in IL-4-stimulated myoblasts, IRS1, which is thought to be tyrosine phosphorylated by activation of Jak 3 (33), is not phosphorylated in the LDM fraction, and that stimulation of glucose transport may require activation of PI 3-kinase in this particular fraction. In accordance with the hypothesis that the activation of PI 3-kinase has to occur in the appropriate subcellular compartment to promote Glut 4 translocation, we found that p110* was present at a high level in the LDM compartment. The localization of p110* paralleled that of endogenous PI 3-kinase. Thus, it suggests that overexpression of p110* did not induce a generalized change in the subcellular distribution of proteins. Furthermore, the lack of SH2 and SH3 domains of p85 in p110* construct did not alter the subcellular localization of PI 3-kinase and the association of PI 3-kinase with membrane fractions. These data would imply that p85 has no targeting role as far as the association of p110 to these membranes is concerned. Interestingly, insulin treatment of cells transfected with p110* led to a further increase in Glut 4 translocation. A possible explanation is that insulin activates a PI 3-kinase-independent signaling pathway. Alternatively, this effect could be due to the activation of endogenous PI 3-kinase by insulin, suggesting that activation of PI 3-kinase is a ratelimiting step for glucose transporter translocation. Future advances in the understanding of the mechanism of Glut 4 translocation will come from the identification of the steps following PI 3-kinase activation. Several studies have focused on the relationship between PI 3-kinase and the small GTPases Rho and Rac. However, a role of Rac in the stimulation of glucose transport seems unlikely because a dominant negative form of this protein did not inhibit this insulin effect, although it blocked insulin-induced ruffling (34) . Novel targets of PI 3-kinase have been identified, such as the Akt/PKB kinase (35) (36) (37) and atypical protein kinase C and protein kinase C (38, 39) . These kinases are activated by phosphatidylinositol 3-phosphate and hence appear as potential players in the Glut 4 translocation machinery. Although the link between PI 3-kinase activation and the production of phosphatidylinositol 3-phosphate and translocation of Glut 4-containing vesicles remains to be determined, our results show that the PI 3-kinase signaling pathway is sufficient to stimulate glucose transporter translocation.
